Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Nov 28;13(12):4295.
doi: 10.3390/nu13124295.

Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Results of a Prospective Phase II Study

Daniel Keizman  1 , Moshe Frenkel  2 , Avivit Peer  2 , Igal Kushnir  3 , Eli Rosenbaum  4 , David Sarid  1 , Ilan Leibovitch  5 , Roy Mano  6 , Ofer Yossepowitch  6 , David Margel  7 , Ido Wolf  1 , Ravit Geva  1 , Hadas Dresler  8 , Keren Rouvinov  9 , Noa Rapoport  3 , Isaac Eliaz  10
Affiliations
Clinical Trial

Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Results of a Prospective Phase II Study

Daniel Keizman et al. Nutrients. .

Abstract

Optimal therapy of biochemically relapsed prostate cancer (BRPC) after local treatment is elusive. An established modified citrus pectin (PectaSol®, P-MCP), a dietary polysaccharide, is an established antagonist of galectin-3, a carbohydrate-binding protein involved in cancer pathogenesis. Based on PSA dynamics, we report on the safety and the primary outcome analysis of a prospective phase II study of P-MCP in non-metastatic BRPC based. Sixty patients were enrolled, and one patient withdrew after a month. Patients (n = 59) were given P-MCP, 4.8 grams X 3/day, for six months. The primary endpoint was the rate without PSA progression and improved PSA doubling time (PSADT). Secondary endpoints were the rate without radiologic progression and toxicity. Patients that did not progress by PSA and radiologically at six months continued for an additional twelve months. After six months, 78% (n = 46) responded to therapy, with a decreased/stable PSA in 58% (n = 34), or improvement of PSADT in 75% (n = 44), and with negative scans, and entered the second twelve months treatment phase. Median PSADT improved significantly (p = 0.003). Disease progression during the first 6 months was noted in only 22% (n = 13), with PSA progression in 17% (n = 10), and PSA and radiologic progression in 5% (n = 3). No patients developed grade 3 or 4 toxicity.

Keywords: PSA doubling time; PectaSol; modified citrus pectin; non-metastatic biochemically relapsed prostate cancer.

PubMed Disclaimer

Conflict of interest statement

IE discloses being the developer of the sponsoring dietary supplement company. The other authors declare no potential conflict of interest.

Figures

Figure 1
Figure 1
Study design. BRPC (Biochemically Relapsed Prostate Cancer); P-MCP (PectaSol® Modified Citrus Pectin); @ 6mo (at six months); ADT (Androgen Deprivation Treatment); PET-PSMA (Positron Emission Tomography-Prostate-Specific Membrane Antigen Scan; CT (Computed Tomography Scan); H&P (History and Physical).
Figure 2
Figure 2
Response to therapy, no progression defined as a decreased/stable PSA and/or improvement of PSADT (n, %).
Figure 3
Figure 3
PSADT risk grouping: pre- versus post-P-MCP (n, %).
Figure 4
Figure 4
Post-P-MCP treatment change of PSADT in different pre-treatment PSADT risk groups (n, %).
See this image and copyright information in PMC

Comment in

  • Urological Oncology: Prostate Cancer.
    Taneja SS. Taneja SS. J Urol. 2022 Jul;208(1):214-216. doi: 10.1097/JU.0000000000002705. Epub 2022 Apr 25. J Urol. 2022. PMID: 35467383 No abstract available.

References

    1. Siegel R.L., Miller K.D., Jemal A. Cancer Statistics. Cancer J. Clin. 2019;69:7–34. doi: 10.3322/caac.21551. - DOI - PubMed
    1. Artibani W., Porcaro A.B., De Marco V., Cerruto M.A., Siracusano S. Management of Biochemical Recurrence after Primary Curative Treatment for Prostate Cancer: A Review. Urol. Int. 2017;100:251–262. doi: 10.1159/000481438. - DOI - PubMed
    1. Keating N.L., O’Malley A.J., Smith M.R. Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate Cancer. J. Clin. Oncol. 2006;24:4448–4456. doi: 10.1200/JCO.2006.06.2497. - DOI - PubMed
    1. Keizman D., Zahurak M., Sinibaldi V., Carducci M., Denmeade S., Drake C., Pili R., Antonarakis E.S., Hudock S., Eisenberger M. Lenalidomide in Nonmetastatic Biochemically Relapsed Prostate Cancer: Results of a Phase I/II Double-Blinded, Randomized Study. Clin. Cancer Res. 2010;16:5269–5276. doi: 10.1158/1078-0432.CCR-10-1928. - DOI - PMC - PubMed
    1. Pound C., Partin A., Eisenberger M., Chan D.W., Pearson J.D., Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591–1597. doi: 10.1001/jama.281.17.1591. - DOI - PubMed

Publication types